Sandoz Group Ag reiterated earnings guidance for the full year 2024. For the year, The company reiterates guidance expecting net sales to grow mid-single digit in constant currencies versus prior year .
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.06 CHF | +1.04% | +0.12% | +18.48% |
May. 22 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
May. 22 | Sandoz Group Receives EU Approval for Cancer, Osteoporosis Biosimilars | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+18.48% | 15.25B | |
+15.91% | 41.97B | |
+22.40% | 22.34B | |
+16.12% | 14B | |
+45.12% | 12.06B | |
-9.58% | 6.8B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+14.18% | 5.49B | |
+4.00% | 4.62B |
- Stock Market
- Equities
- SDZ Stock
- News Sandoz Group AG
- Sandoz Group Ag Reiterates Earnings Guidance for the Full Year 2024